Bing Zhao

Corporate Officer/Principal presso H&J Cro International, Inc. /CN/

Health Technology

Consumer Services

Posizioni attive di Bing Zhao

Società	Posizione	Inizio	Fine
H&J Cro International, Inc. /CN/	Corporate Officer/Principal	-	-
Rundo-Cronova Intl Pharms Research & Development Co., Ltd.	Corporate Officer/Principal	-	-
Guangzhou Osmunda Medical Device Technical Service Co., Ltd. Guangzhou Osmunda Medical Device Technical Service Co., Ltd. Medical SpecialtiesHealth Technology Guangzhou Osmunda Medical Device Technical Service Co., Ltd. engages in providing service in the medical device field. The company was founded in February 2004 and is headquartered in Guangzhou, China.	Corporate Officer/Principal	-	-

Società	Posizione	Inizio	Fine
XYNOMIC PHARMACEUTICALS HOLDINGS, INC.	Direttore Tecnico/Scientifico/R&S	-	-
XYNOMIC PHARMACEUTICALS HOLDINGS, INC.	Consigliere Generale	-	-

Xi'an Jiaotong University Health Science Center

Doctorate Degree

Distribuzione geografica

Cina

Posizioni

Corporate Officer/Principal	3
Chief Tech/Sci/R&D Officer	1
General Counsel	1

Settori

Health Technology	3
Consumer Services	2

Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Aziende private	4
Rundo-Cronova Intl Pharms Research & Development Co., Ltd.
Guangzhou Osmunda Medical Device Technical Service Co., Ltd. Guangzhou Osmunda Medical Device Technical Service Co., Ltd. Medical SpecialtiesHealth Technology Guangzhou Osmunda Medical Device Technical Service Co., Ltd. engages in providing service in the medical device field. The company was founded in February 2004 and is headquartered in Guangzhou, China.	Health Technology
Xynomic Pharmaceuticals Holdings, Inc. Xynomic Pharmaceuticals Holdings, Inc. Pharmaceuticals: MajorHealth Technology Xynomic Pharmaceuticals Holdings, Inc. is a clinical stage best-in-class oncology therapeutics biopharmaceutical company. It engages in licensing, developing and commercializing oncology drug candidates in China, US, and rest of the world. Its current pipeline mainly consists of 3 drug candidates; Xynomic owns global exclusive development, manufacturing and commercialization rights to each of these. Its lead drug candidate abexinostat is in global potentially pivotal clinical trials against renal cell carcinoma and non-Hodgkin's lymphoma. The company was founded by Yinglin Mark Xu on October 7, 2016 and is headquartered in Shanghai, China.	Health Technology
H&J Cro International, Inc. /CN/